Early Flu Shots: Argentina Launches Advance Vaccination Campaign 2024
Argentina is moving forward with its annual influenza vaccination campaign earlier than usual this year, beginning . This proactive step is in response to the detection of a new variant of the influenza A virus – H3N2, subclade K – and anticipation of increased circulation of respiratory viruses.
Health officials emphasize the importance of early vaccination to protect vulnerable populations and mitigate potential strain on the public health system. While the H3N2, subclade K variant does not appear to cause more severe illness, its increased contagiousness raises concerns about a surge in cases. The Ministry of Health has secured 8.16 million doses of influenza vaccine to ensure nationwide availability, with an initial delivery of 795,760 doses – including both adjuvanted and adult formulations – already underway this week.
Changing Epidemiology Drives Earlier Campaign
The decision to begin the vaccination campaign earlier reflects a shift in the typical seasonal patterns of respiratory viruses. Authorities have observed that influenza and other respiratory viruses are beginning to circulate earlier in the year than in previous seasons. This change in behavior prompted the Ministry of Health to act proactively to protect the population before the peak of viral circulation, which typically occurs during the autumn and winter months.
“We are anticipating the usual calendar to protect the population before the peak of viral circulation. Each year, respiratory viruses begin to circulate earlier. That’s why we decided to act early to avoid the possible impact of the new variants and care for those who need it most,” stated Minister of Health Mario Lugones. He also highlighted the logistical effort involved in accelerating the campaign, made possible by efficient resource management.
Who is Eligible for Vaccination?
The vaccination campaign prioritizes several key groups, including children aged 6 to 24 months, adults over 65, healthcare personnel, pregnant and postpartum women, and individuals with underlying health conditions. Specifically, 4.7 million doses are allocated for adults aged 2 to 64 with risk factors.
Individuals with chronic medical conditions are also strongly encouraged to receive the influenza vaccine. These conditions include respiratory diseases, cardiovascular diseases, metabolic disorders, and immunological conditions. People with obesity, diabetes, or kidney disease are also considered at higher risk and are recommended to get vaccinated.
Health officials underscore that the influenza vaccine is safe, effective, and supported by extensive scientific evidence. Annual vaccination is recommended due to the virus’s tendency to mutate, necessitating updates to the vaccine formulation each year.
Vaccination of healthcare personnel is particularly important, as it helps reduce transmission within healthcare settings and protects vulnerable patients. Early immunization also contributes to maintaining the capacity of the healthcare system during periods of high demand.
Broader Global Efforts to Combat Influenza
The focus on influenza vaccination in Argentina aligns with broader global efforts to enhance pandemic preparedness. A new initiative, led by the Argentinian manufacturer Sinergium Biotech, aims to accelerate the development and accessibility of mRNA vaccines against avian influenza (H5N1). This project is part of the World Health Organization (WHO) and Medicines Patent Pool (MPP) mRNA Technology Transfer Programme, designed to build vaccine production capacity in low- and middle-income countries.
While this initiative focuses on H5N1, it underscores the importance of ongoing research and development in influenza vaccines to address emerging threats and improve protection against seasonal strains. Recent data from five South American countries – Argentina, Brazil, Chile, Paraguay, and Uruguay – indicate that the 2024 Southern Hemisphere influenza vaccine reduced the risk of influenza-associated hospitalization among high-risk groups by 35%. This suggests that similar vaccine effectiveness may be observed in the Northern Hemisphere during the 2024-2025 influenza season if similar A(H3N2) viruses predominate.
The Ministry of Health is coordinating with provinces to implement the vaccination campaign, ensuring that vaccines are distributed efficiently and are accessible in healthcare centers and hospitals. Provinces will define specific vaccination schedules and locations based on their local healthcare organization.
Specialists emphasize that vaccination not only protects the individual receiving the vaccine but also reduces viral circulation within the community, providing indirect protection to those who cannot be vaccinated for medical reasons. The early start to the 2026 campaign reflects a comprehensive strategy to prevent outbreaks and reduce the burden on the healthcare system during the upcoming respiratory virus season.